Chardan Capital analyst Daniil Gataulin maintained a Hold rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target ...

Chardan Capital Markets has recently initiated Mind Medicine (MindMed) Inc (MNMD) stock to Buy rating, as announced on December 20, 2024, according to Finviz. Earlier, on October 14, 2024, Leerink ...

Fintel reports that on January 10, 2025, Chardan Capital initiated coverage of Unity Biotechnology (NasdaqGS:UBX) with a Buy ...

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) have been assigned an average recommendation of “Buy” ...

Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics ...

Eyenovia (EYEN) has engaged Chardan as its financial advisor in connection with its evaluation of strategic alternatives. With assistance from ...

On Friday, Chardan Capital Markets began coverage of Unity Biotechnology Inc (NASDAQ:UBX) shares with a Buy rating and a $6.00 price target, representing significant upside from the current price ...

Fintel reports that on January 10, 2025, Chardan Capital initiated coverage of Unity Biotechnology (LSE:0YC0) with a Buy recommendation. There are 52 funds or institutions reporting positions in ...

With assistance from Chardan, the Company will continue to assess a full range of strategic alternatives, including but not limited to, a business combination, sale of the Company, reverse merger ...

Eyenovia, Inc., an ophthalmic technology company, has announced it is consulting with Chardan as its financial advisor to explore various strategic alternatives, including potential business ...

On Friday, Chardan Capital Markets began coverage of Unity Biotechnology Inc (NASDAQ:UBX) shares with a Buy rating and a $6.00 price target, representing significant upside from the current price of ...